In the CheckMate 067 trial, nivolumab monotherapy maintained a stable global health status in patients with advanced melanoma, with no significant deterioration over time compared with ipilimumab (CTLA-4 inhibitor), which has also been shown to maintain a stable HRQL in this population [6]. Here, CTLA4 is linked to melanoma.